CHEK2 and glioblastoma: Moreover, irrespective of MGMT-dependent repair, CD133-positive GBM cells preferentially activate the checkpoint kinases 1 (Chk1) and 2 (Chk2), the key regulators of DNA checkpoint signaling, to repair DNA damage more effectively than autologous CD133-negative GBM cells [21].